Entropy NeurodynamicsASX:ENP -3.23% ROA % is -87.23% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 1,423 Biotechnology companies, Entropy Neurodynamics ranks worse than 73.23% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Entropy Neurodynamics's annualizedNet Income for the quarter that ended in Dec. 2025 was A$-6.86 Mil.
Entropy Neurodynamics's average Total Assets over the quarter that ended in Dec. 2025 was A$7.87 Mil. Therefore, Entropy Neurodynamics's annualized ROA % for the quarter that ended in Dec. 2025 was -87.23%.
The historical rank and industry rank for Entropy Neurodynamics's ROA % or its related term are showing as below:
ASX:ENP'
s ROA % Range Over the Past 10 Years
Min: -88.4 Med: -66.82 Max: -36.25
Current: -67.58
During the past 7 years, Entropy Neurodynamics's highest ROA % was -36.25%. The lowest was -88.40%. And the median was -66.82%.
ASX:ENP's ROA % is ranked worse than 73.23% of 1423
companies
in the Biotechnology industry
Industry Median: -33.07
vs ASX:ENP: -67.58
Entropy Neurodynamics (ASX:ENP) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entropy Neurodynamics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entropy Neurodynamics ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's ROA % distribution charts can be found below:
* The bar in red indicates where Entropy Neurodynamics's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Entropy Neurodynamics (ASX:ENP) has a ROA % of -87.23% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Entropy Neurodynamics and its competitors. According to the industry distribution chart, Entropy Neurodynamics ranks #1042 out of 1423 companies in the Biotechnology industry, placing it in the top 73.2%.
Is Entropy Neurodynamics' ROA % too high?
Entropy Neurodynamics' current ROA % is -87.23%. Based on the distribution chart, Entropy Neurodynamics ranks #1042 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint.
How does Entropy Neurodynamics' ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #1042 out of 1423 companies for ROA %. This places Entropy Neurodynamics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Entropy Neurodynamics and its competitors. Entropy Neurodynamics's current ROA % is -87.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (ASX:ENP) is currently considered Fairly Valued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.03 — trading right at its estimated fair value. The current ROA % is -87.23%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Entropy Neurodynamics (ASX:ENP), the current ROA % is -87.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ENP has been successfully added to your 